Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 clinical trial were presented.

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...